31 – 40 of 59
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Treatment of aggressive pituitary tumours and carcinomas : results of a European Society of Endocrinology (ESE) survey 2016
(
- Contribution to journal › Article
-
Mark
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
(
- Contribution to journal › Article
- 2017
-
Mark
Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly
(
- Contribution to journal › Article
-
Mark
A permissive role of growth hormone (GH) in the development of second brain tumors after radiotherapy?
(
- Contribution to journal › Letter
-
Mark
Radiotherapy, especially at young age, increases the risk for de novo brain tumors in patients treated for pituitary/sellar lesions
(
- Contribution to journal › Article
-
Mark
Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency : a phase 3b, open-label, extension study
(
- Contribution to journal › Article
-
Mark
Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort
(
- Contribution to journal › Article
- 2016
-
Mark
Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
(
- Contribution to journal › Article
-
Mark
GH Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults.
(
- Contribution to journal › Article
- 2015
-
Mark
ESE guidelines, why and how.
(
- Contribution to journal › Debate/Note/Editorial